LORNOXICAM: A REVIEW OF ITS THERAPEUTIC POTENTIAL IN DIFFERENT CLINICAL STUDIES

Authors

  • Sushila Godara Post Graduate Institute of Medical Sciences, Rohtak
  • R K Srivastava Post Graduate Institute of Medical Sciences, Rohtak
  • Rajesh Godara Post Graduate Institute of Medical Sciences, Rohtak
  • Garima Bhutani Post Graduate Institute of Medical Sciences, Rohtak, BPS, govt. medical college, Khanpur Kalan Sonipat, Haryana, India.

Abstract

Lornoxicam is a member of the oxicam group of nonsteroidal antiinflammatory drugs (NSAIDs), producing analgesic and antipyretic effects  through the non-selective inhibition of cyclo-oxygenase-1 and -2. Besides its inhibitory effect on COX1 and COX-2 peripheral receptors, is also increases endogenous dinorphin and beta-endorphin levels promoting central analgesic and anti-inflammatory effects. Recently, lornoxicam has been introduced in Indian market in oral, intravenous and intramuscular formulations.  Lornoxicam is completely absorbed after oral administration, reaching peak plasma concentrations of 280 mg/L within 2.5 hours after a 4 mg dose.  After intramuscular injection maximum plasma concentrations are achieved after approximately 20-25 minutes. Lornoxicam is extensively metabolished in liver by cytochrome P4502DC9 to inactive metabolite 5’-hydroxy-lornoxicam. The mean elimination half life is 3 to 4 hours. There is plenty of literature available on the effect of lornoxicam on chronic and acute pain management. These preliminary finding require confirmation in further comparative studies.

Key words:- lornoxicam, analgesic, anti inflammatory drugs.

DOI

https://doi.org/10.22270/jddt.v3i2.403

Published

15-03-2013
Statistics
Abstract Display: 1037
PDF Downloads: 1229

How to Cite

1.
Godara S, Srivastava RK, Godara R, Bhutani G. LORNOXICAM: A REVIEW OF ITS THERAPEUTIC POTENTIAL IN DIFFERENT CLINICAL STUDIES. J. Drug Delivery Ther. [Internet]. 2013 Mar. 15 [cited 2025 May 14];3(2). Available from: https://jddtonline.info/index.php/jddt/article/view/403

Issue

Vol. 3 No. 2 (2013): Volume 3, Issue 2, March-April, 2013

Section

Review

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

How to Cite

1.
Godara S, Srivastava RK, Godara R, Bhutani G. LORNOXICAM: A REVIEW OF ITS THERAPEUTIC POTENTIAL IN DIFFERENT CLINICAL STUDIES. J. Drug Delivery Ther. [Internet]. 2013 Mar. 15 [cited 2025 May 14];3(2). Available from: https://jddtonline.info/index.php/jddt/article/view/403
Crossref
Scopus
Google Scholar
Europe PMC